Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma
In real-world practice, three-quarters of la/mUC patients treated with EV receive no subsequent bladder-directed therapy. When employed early, radical cystectomy was associated with the longest survival, supporting multidisciplinary evaluation of surgical consolidation in select EV responders. Prospective trials are warranted to define patient selection, timing, and comparative efficacy of surgery vs. radiotherapy in the EV era.
Authors
- Laura Bukavina (ORCID: https://orcid.org/0000-0001-7129-6230)
- Betty Wang (ORCID: https://orcid.org/0000-0003-1926-2468)
- Rahul D. Tendulkar (ORCID: https://orcid.org/0000-0002-6633-0577)
- Shalini Moningi (ORCID: https://orcid.org/0000-0003-2638-8202)
- Amanda Nizam
- Laura Davis
- Christopher Weight
- Jason Brown
Institutions
- Cleveland Clinic (US)
- University Hospitals of Cleveland (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.urolonc.2026.110994
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00